{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:15:32Z","timestamp":1772241332156,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cllc.2016.09.003","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T23:31:10Z","timestamp":1477697470000},"page":"e223-e232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-3207","authenticated-orcid":false,"given":"Michal","family":"Sarfaty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Neiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Dudnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Ilouze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Gottfried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rivka","family":"Katznelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hovav","family":"Nechushtan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas Gantz","family":"Sorotsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton","family":"Saute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Wolner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mor","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doron","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siraj","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior Soussan","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addie","family":"Dvir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2016.09.003_bib1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2016.09.003_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2016.09.003_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2016.09.003_bib4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JTO.0000000000000135","article-title":"Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma","volume":"9","author":"Mizukami","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A\u00a0transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.cllc.2016.09.003_bib6","article-title":"Comprehensive genomic profiling (CGP) of 44 RET-fused lung adenocarcinomas (LADCA) with histologic and clinical correlates","volume":"475A","author":"Elvin","year":"2015","journal-title":"Lab Invest"},{"key":"10.1016\/j.cllc.2016.09.003_bib7","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/JTO.0b013e31828a4d07","article-title":"A\u00a0patient with lung adenocarcinoma and RET fusion treated with vandetanib","volume":"8","author":"Gautschi","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib8","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1200\/JCO.2013.50.5016","article-title":"Effect of the RET inhibitor vandetanib in a patient with RET fusion\u2013positive metastatic non\u2013small-cell lung cancer","volume":"34","author":"Falchook","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A\u00a0pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Hidalgo","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2016.09.003_bib10","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non\u2013small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2012.42.9829","article-title":"New targetable oncogenes in non\u2013small-cell lung cancer","volume":"31","author":"Oxnard","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib versus placebo in patients with advanced non\u2013small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib13","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1535-7163.MCT-14-0274","article-title":"Alectinib shows potent antitumor activity against RET-rearranged non\u2013small cell lung cancer","volume":"13","author":"Kodama","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2016.09.003_bib14","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/jco.2012.30.15_suppl.5508","article-title":"An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline","volume":"30","author":"Schoffski","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov"},{"issue":"suppl","key":"10.1016\/j.cllc.2016.09.003_bib16","article-title":"Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers","volume":"33","author":"Drilon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2016.09.003_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","article-title":"Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer","volume":"20","author":"Pekar-Zlotin","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2016.09.003_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cllc.2016.09.003_bib22","doi-asserted-by":"crossref","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730416302285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730416302285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:05:55Z","timestamp":1761505555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730416302285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1525730416302285"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2016.09.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2016.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}